Clinical trial • Phase I • Oncology
nivolumab for Non-small cell lung cancer
Phase I trial of nivolumab for Non-small cell lung cancer. 20 participants.
Overview
- Trial Therapeutic Area
- Oncology
- Trial Disease
- Non-small cell lung cancer
- Trial Stage
- Phase I
- Drug Modality
- Other | Monoclonal antibody
Key dates
- Initial CTIS Submission Date
- 28-06-2024
- First CTIS Authorization Date
- 03-10-2024
Trial design
Phase I trial across 1 site in France.
- Target Sample Size
- 20
Recruitment
- Planned Sample Size
- 20
- Recruitment Window Months
- 84
Geography
- Total Number Of Sites
- 1
- Total Number Of Participants
- 20
France
- Earliest CTIS Part Ii Submission Date
- 09-09-2024
- Latest Decision Or Authorization Date
- 03-10-2024
- Processing Time Days
- 24
- Number Of Sites
- 1
- Number Of Participants
- 20
Sites
- Site Name
- Institut Curie
- Department Name
- Departement oncologie medicale
- Contact Person Name
- Nicolas Girard
- Contact Person Email
- nicolas.girard2@curie.fr
Sponsor
Primary sponsor
- Full Name
- Transgene
- Organisation Type
- Pharmaceutical company
- Country Of Registered Address
- France
Investigational products
- Investigational Product Name
- TG4050
- Modality
- Other
- Investigational Product Name
- nivolumab
- Active Substance
- nivolumab
- Modality
- Monoclonal antibody
- Combination Treatment
- Yes
Related trials
Other published trials that may interest you.